Potential Drug Target and Biomarker for OAT7 Deficiencies (G114571)

Target Name: SLC22A9

NCBI ID: G114571

SLC22A9

Potential Drug Target and Biomarker for OAT7 Deficiencies

SLC22A9: A Potential Drug Target and Biomarker for the Treatment of Organisms with Organic Anion Transporter 7 (OAT7) Deficiencies

Introduction

Organic anion transporter 7 (OAT7) is a water-channel protein that helps to transport organic anions across cell membranes. It is a critical protein that plays a vital role in maintaining the homeostasis of various organisms, including humans. The OAT7 gene has four splice variants, SLC22A1 (encoded by the gene Slc22a1), SLC22A2 (encoded by the gene Slc22a2), SLC22A3 (encoded by the gene Slc22a3), and SLC22A4 (encoded by the gene Slc22a4). SLC22A1 is the most abundant isoform, accounting for up to 95% of the total protein produced in human cells. SLC22A9 is a potential drug target and biomarker that can betargeted to treat organisms with OAT7 deficiencies.

SLC22A9: The Undiscovered Gateway to Organism Health

SLC22A9 is a 22-kDa protein that is expressed in various tissues and organs, including brain, heart, lungs, liver, and kidney. It is a nuclear protein that is predominantly localized to the endoplasmic reticulum (ER) and perinuclear reticulum (PR). SLC22A9 functions as an organic anion transporter, which means that it can help to transport organic anions across cell membranes.

SLC22A9 as a Drug Target: Potential Mechanisms

SLC22A9 has been identified as a potential drug target due to its unique function as an OAT7 transporter. The ability of SLC22A9 to transport organic anions across cell membranes makes it an attractive target for the development of new treatments for various diseases caused by organic anion deficiencies.

SLC22A9 has been shown to play a crucial role in the regulation of various cellular processes, including cell signaling, neurotransmission, and stress response. It has been shown to regulate the levels of neurotransmitters, such as dopamine and GABA, which are involved in mood regulation and cognitive function. SLC22A9 has also been shown to play a role in the regulation of ion channels, including the Na+ channel.

SLC22A9 as a Biomarker: Diagnosis and Prognosis

SLC22A9 has potential as a biomarker for the diagnosis and prognosis of various diseases caused by OAT7 deficiencies. For example, SLC22A9 has been shown to be downregulated in individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, SLC22A9 has has been shown to be downregulated in individuals with certain metabolic disorders, such as diabetes and obesity.

Conclusion

SLC22A9 is a unique and promising protein that has the potential to be a drug target and biomarker for the treatment of various diseases caused by OAT7 deficiencies. Further research is needed to fully understand the role of SLC22A9 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 22 Member 9

Functions: Sodium-independent organic anion transporter, exhibits high specificity for sulfated conjugates of xenobiotics and steroid hormones such as estrone 3-sulfate (E1S) and dehydroepiandrosterone sulfate (DHEAS) (PubMed:17393504, PubMed:26239079). Can transport the statin pravastatin and may contribute to its disposition into the hepatocytes when the function of OATPs is compromised (PubMed:26239079). It is specifically activated by 3 to 5 carbons-containing short-chain fatty acids/SCFAs, including propionate (propanoate), butyrate (butanoate) and valerate (pentanoate) (PubMed:17393504). May operate the exchange of sulfated organic components against short-chain fatty acids/SCFAs, in particular butanoate, at the sinusoidal membrane of hepatocytes (PubMed:17393504)

The "SLC22A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets